| 摘要: |
| 本文基于欧洲药品管理局(EMA)2010年发布的《生物等效性研究指南》(Rev.1版本)及2020年至2021年发布的临床药理学与药代动力学问答文件(Q&A)中第6.4和6.5部分,系统解析了EMA对于多规格化学药品复方制剂基于已通过生物等效性(BE)试验的规格,对其他规格申请BE豁免的处方相似性要求,为国内复方制剂研发与注册提供科学参考。 |
| 关键词: 欧洲药品管理局 多规格复方制剂 生物等效性试验豁免 处方相似性 |
| DOI:10.13506/j.cnki.jpr.2025.09.008 |
| 基金项目: |
|
Publication Date:September 25, 2025
|
|
| Analysis of formulation similarity requirements for biowaiver of bioequivalence studies in multi-strength fixed-dose combinations by the European Medicines Agency |
| CHEN Si,MI Xianwei,SHI Jing |
| (Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China) |
| Abstract: |
| This article systematically analyzes the European Medicines Agency (EMA)'s requirements for formulation similarity when applying for bioequivalence (BE) waivers for other specifications of multi-specification chemical compound pharmaceutical preparations, based on specifications that have already passed BE trials. The analysis is conducted in accordance with Investigation of bioequivalence - Scientific guideline (Rev.1, 2010) and Clinical pharmacology and pharmacokinetics: questions and answers (Sections 6.4 and 6.5, 2020—2021) issued by EMA. The findings aim to provide scientific references for the development and registration of FDCs in domestic markets. |
| Key words: EMA Multi-strength fixed-dose combinations Biowaiver of bioequivalence studies Formulation similarity requirements |